WO2007085087A1 - Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects - Google Patents
Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects Download PDFInfo
- Publication number
- WO2007085087A1 WO2007085087A1 PCT/CA2007/000111 CA2007000111W WO2007085087A1 WO 2007085087 A1 WO2007085087 A1 WO 2007085087A1 CA 2007000111 W CA2007000111 W CA 2007000111W WO 2007085087 A1 WO2007085087 A1 WO 2007085087A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subjects
- nucleic acid
- genotype
- vasopressin
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Vasopressin Pathway Polymorphisms as Indicators of Subject Outcome in Critically 111 Subjects
- the field of the invention relates to the assessment and/or treatment of subjects with an inflammatory condition.
- Arginine vasopressin has both vasoconstrictor and anti-diuretic properties.
- AVP is synthesized in the hypothalamus and secreted from posterior pituitary gland, secreted into the circulation and binds to several receptors.
- AVP binds to vasopressin-specific membrane bound receptor AVPRlA on vascular smooth muscle (MOUILLAC B. et al. J Biol Chem (1995) 270: 25771-25777), AVPR2 in the distal convoluted tubule and collecting ducts in the kidney and AVPRlB pituitary receptors that modify adrenocorticotropin hormone (ACTH) production (ORLOFF J. and HANDLER J.
- ACTH adrenocorticotropin hormone
- AVP leucyl/cystinyl aminopeptidase
- AVP does not contribute much to the maintenance of blood pressure (GROLLMAN J Pharm Exper Therap ( 1932) 46:447-460; GRAYBIEL Am Heart J (1941) 21:481-489; and WAGNER, J Clin Invest (1956) 35: 1412-1418).
- AVP is fundamental to the response to hypotension as AVP is released from the posterior pituitary and causes arterial smooth muscle to contract (vasoconstriction) (WAGNER, J Clin Invest (1956) 35: 1412-1418; AISENBREY J Clin Invest (1981) 67:961-968; and SCHWARTZ Endocrinology (1981) 108: 1778-1780). If AVP is not secreted by the posterior pituitary in response to hypotension, then blood pressure remains low or falls further as a result of inappropriate vasodilation.
- AVP can be administered to subjects who have septic shock who are not responding adequately. It has been reported that AVP increases blood pressure, decreases need for vasopressors such as norepinephrine, and increases urine output (LANDRY DW et al. Circulation. (1997) 95: 1122-1125; HOLMES CL et al. Int. Care Med. (2001) 27: 1416-1421).
- Vasopressin is commonly used after cardiac surgery as studies have shown that AVP levels are lower after cardiac surgery compared to baseline.
- AVP infusion has been demonstrated to increase blood pressure after cardiac surgery (ARGENZIANO J Circulation (1997) 96(9 Suppl):II-286-90; ARGENZIANO J Thorac. Cardiovasc Surg. (1998) 116(6):973-80; CHEN Circulation (1999) 100(19 Suppl):II244-6; and ROSENZWEIG Circulation (1999) 100(19 Suppl):II182-6).
- Arginine vasopressin also known as antidiuretic hormone or ADH
- AVP AVP - neurophysin II gene
- AVP is synthesized in the hypothalamus as a precursor polypeptide (prepro-AVP-NPII) and undergoes post-translational processing to yield three functional peptides: AVP, NPII, and copeptin (Entrez Gene; http://www.ncbi.nlm.nih.gov/entrez).
- the AVP-NPl 1 complex is transported along nerve axons to the posterior pituitary where it is secreted into the bloodstream or directly into the brain.
- _AVP acts to maintain fluid homeostasis by signaling through AVPR2 receptors in the collecting ducts of the kidney (BIRNB AUMER M Trends Endocrinol Metab (2000) 10:406-10) and plays a role in pH regulation (TASHEVIA Y et al Plufgers Arch (2001) 442(5):652-61. Furthermore, AVP is thought to be involved in cognition, tolerance, adaptation as well as complex sexual and maternal behavior (YOUNG WS et al Neurosci (2006) 143(4): 1031-9). A representative human AVP mRNA sequence is listed in GenBank under accession numbers NM_00490 (633 bp). NM 00490 contains AVP rs 1410713 but not rs857242.
- AVPRlA Human arginine vasopressin receptor IA
- VIaR Via vasopressin receptor
- SCCL vasopressin subtype Ia receptor
- Vl-vascular vasopressin receptor Vl-vascular vasopressin receptor
- antidiuretic hormone receptor IA vascular/hepatic -type arginine vasopressin receptor
- AVPRlA maps to chromosomal region 12ql4-ql5.
- the protein encoded by this gene acts as receptor for arginine vasopressin (AVP).
- AVP arginine vasopressin
- This receptor belongs to the subfamily of G-protein coupled receptors which also includes AVPRlB, AVPR2 and OXTR.
- AVPRlA agonist binding increases intracellular calcium concentrations by signaling through the phospholipase C cascade (OMM: 600821).
- OMM phospholipase C cascade
- the downstream effects of this signaling cascade include cell contraction and proliferation, platelet aggregation, release of coagulation factors and glycogenolysis.
- AVPRlA has been investigated for associations with social behaviors, including affiliation and attachment (YOUNG LJ et al Nature (1999) 400(6746):766-8) as well as essential hypertension (THIBONNIER M et al l MoI Cell Cardiol (2000) 32(4):557-564).
- a representative human AVPRlA mRNA sequence is listed in GenBank under accession number NM_000706 (4154 bp).
- the NM_000706 sequence contains AVPRlA SNP rs3803107 (and rslO42615), but not rsl495027 or rsl0877970.
- LNPEP Homo sapiens leucyl/cystinyl aminopeptidase
- AT (4) receptor angiotensin IV receptor
- insulin-regulated aminopeptidase insulin-responsive aminopeptidase
- insulin-responsive aminopeptidase insulin-responsive aminopeptidase
- otase oxytocinase
- placental leucine aminopeptidase and vasopressinase.
- LNPEP maps to chromosomal region 5ql5.
- the LNPEP gene encodes a metalloproteinase that cleaves polypeptides such as vasopressin, oxytocin, lys-bradykinin, met-enkephalin and dynorphin A (Entrez Gene: www.ncbi.nlm.nih.gov/entrez). LNPEP also catalyzes the conversion of angiotensinogen to angiotensin IV (AT4) and is thought to play a role in memory processing by acting as a receptor for AT4 (LEW RA et al J Neurochem (2003) 86(2):344-50. LNPEP also plays a role in the maintenance of pregnancy (NORMURA S et al Biochim Biophys Acta (2005) 1751(l): 19-25).
- LNPEP LNPEP mRNA sequence
- GenBank GenBank under accession number NM_005575 (4470 bp).
- the NM_005575 sequence does not contain the LNPEP SNP rs 18059.
- Homo sapiens leukocyte-derived arginine aminopeptidase (LRAP) is also known as endoplasmic reticulum aminopeptidase 2; (ERAP2).
- LRAP maps to chromosomal region 5ql5, immediately upstream of LNPEP.
- the longest annotated transcript of LRAP (NM 022350) has 18 exons and is predicted to encode a protein of 915 amino acids (aa).
- LRAP is localized to the endoplasmic reticulum (ER) of the cell where it functions to cleave antigenic peptides greater than nine aa for presentation to major histocompatibility complex 1 (MHC-I) molecules (TANIOKA T et al J Biol Chem (2003) 278(34):32275-83).
- MHC-I major histocompatibility complex 1
- a representative human LRAP mRNA sequence is listed in GenBank under accession number NM_022350 (3356 bp).
- Genotype has been shown to play a role in the prediction of subject outcome in inflammatory and infectious diseases (MCGUIRE W. et al. Nature (1994) 371 :508-10; NADEL S. et al. Journal of Infectious Diseases (1996) 174:878-80; MIRA JP. et al. JAMA (1999) 282:561-8; MAJETSCHAK M. et al. Ann Surg (1999) 230:207-14; STUBER F. et al. Crit Care Med (1996) 24:381-4; STUBER F. et al. Journal of Inflammation (1996) 46:42-50; and WEITKAMP JH. et al. Infection (2000) 28:92-6).
- genotype can alter response to therapeutic interventions.
- Genentech's HERCEPTIN® was not effective in its overall Phase III trial but was shown to be effective in a genetic subset of subjects with human epidermal growth factor receptor 2 (HER2)- positive metastatic breast cancer.
- Novartis' GLEEVEC® is only indicated for the subset of chronic myeloid leukemia subjects who carry a reciprocal translocation between chromosomes 9 and 22.
- This invention is based in part on the surprising discovery that vasopressin pathway SNPs from AVP, AVPRlA, LNPEP and LRAP are predictive or indicative of subject outcome, wherein subject outcome is the ability of the subject to recover from an inflammatory condition based on having a particular AVP, AVPRlA, LNPEP or LRAP genotype as compared to a subject not having that genotype.
- vasopressin pathway SNPs having an association with improved prognosis or subject outcome, in subjects with an inflammatory condition.
- various vasopressin pathway SNPs are provided which are useful for subject screening, as an indication of subject outcome, or for prognosis for recovery from an inflammatory condition.
- This invention is also based in part on the identification that the particular nucleotide (allele) or genotype at the site of a given SNP may be associated with a decreased likelihood of recovery from an inflammatory condition ('risk genotype') or an increased likelihood of recovery from an inflammatory condition ('decreased risk genotype'). Furthermore, this invention is in part based on the discovery that the genotype or allele may be predictive of increased responsiveness to the treatment of the inflammatory condition with vasopressin receptor agonist (i.e. "adverse response genotype” (ARG) or "improved response genotype” (IRG)).
- the vasopressin receptor agonist may be vasopressin.
- the inflammatory condition may be SIRS, sepsis or septic shock.
- This invention is also based in part on the surprising discovery that AVP, AVPRlA LNPEP and LRAP SNPs alone or in combination are useful in predicting the response a subject with an inflammatory condition will have to vasopressin receptor agonist treatment or vasopressin treatment. Whereby the subjects having an improved response genotype are more likely to benefit from and have an improved response to vasopressin receptor agonist treatment and subjects having a non-improved response genotype are less likely to benefit from the same treatment.
- AVP AVPRlA LNPEP
- LRAP SNPs and SNPs in linkage disequilibrium (LD) thereto which are also useful in predicting the response a subject with an inflammatory condition will have to vasopressin receptor agonist treatment or vasopressin treatment.
- methods for obtaining a prognosis for a subject having, or at risk of developing, an inflammatory condition, the method including determining a genotype of said subject which includes one or more polymorphic sites in the subject's vasopressin pathway gene sequences or a combination thereof, wherein said genotype is indicative of an ability of the subject to recover from the inflammatory condition.
- methods for identifying a polymorphism in a vasopressin pathway gene sequence that correlates with prognosis of recovery from an inflammatory condition, the method including: obtaining vasopressin pathway gene sequence information from a group of subjects having an inflammatory condition; identifying at least one polymorphic nucleotide position in the vasopressin pathway gene sequence in the subjects; determining a genotypes at the polymorphic site for individual subjects in the group; determining recovery capabilities of individual subjects in the group from the inflammatory condition; and correlating the genotypes determined in step (c) with the recovery capabilities determined in step (d) thereby identifying said vasopressin pathway gene sequence polymorphisms that correlate with recovery.
- a kit for determining a genotype at a defined nucleotide position within a polymorphic site in vasopressin pathway gene sequence in a subject to provide a prognosis of the subject's ability to recover from an inflammatory condition, the kit including: a restriction enzyme capable of distinguishing alternate nucleotides at the polymorphic site; or a labeled oligonucleotide having sufficient complementary to the polymorphic site so as to be capable of hybridizing distinctively to said alternate.
- the kit may further include an oligonucleotide or a set of oligonucleotides operable to amplify a region including the polymorphic site.
- the kit may further include a polymerization agent.
- the kit may further include instructions for using the kit to determine genotype.
- methods for treating an inflammatory condition in a subject in need thereof, the method including administering to the subject a vasopressin receptor agonist, wherein said subject has an improved response genotype in their vasopressin pathway associated gene sequence.
- methods for treating an inflammatory condition in a subject in need thereof, the method including: selecting a subject having an improved response genotype in their vasopressin pathway associated gene sequence; and administering to said subject one or more vasopressin receptor agonist(s).
- methods for treating a subject with an inflammatory condition by administering a vasopressin receptor agonist, the method including administering the vasopressin receptor agonist to subjects that have an improved response genotype in their vasopressin pathway associated gene sequence, wherein the improved response genotype is predictive of increased responsiveness to the treatment of the inflammatory condition with a vasopressin receptor agonist.
- methods for identifying a subject with increased responsiveness to treatment of an inflammatory condition with a vasopressin receptor agonist, including the step of screening a population of subjects to identify those subjects that have an improved response genotype in their vasopressin pathway associated gene sequence, wherein the identification of a subject with an improved response genotype in their vasopressin pathway associated gene sequence is predictive of increased responsiveness to the treatment of the inflammatory condition with the vasopressin receptor agonist.
- methods are provided for selecting a subject for the treatment of an inflammatory condition with a vasopressin receptor agonist, including the step of identifying a subject having an improved response genotype in their vasopressin pathway associated gene sequence, wherein the identification of a subject with the improved response genotype is predictive of increased responsiveness to the treatment of the inflammatory condition with the vasopressin receptor agonist.
- methods for treating an inflammatory condition in a subject, the method including administering a vasopressin receptor agonist to the subject, wherein said subject has an improved response genotype in their vasopressin pathway associated gene sequence.
- methods for treating an inflammatory condition in a subject, the method including: identifying a subject having an improved response genotype in their vasopressin pathway associated gene sequence; and administering a vasopressin receptor agonist to the subject.
- vasopressin receptor agonist(s) are provided for administering one or more vasopressin receptor agonist(s) to a subject in need thereof, said subject having an improved response genotype in their vasopressin pathway associated gene sequence.
- methods are provided for treating an inflammatory condition in a subject, the method including: identifying a subject having an adverse response genotype in their vasopressin pathway associated gene sequence; and selectively not administering a vasopressin receptor agonist to the subject.
- methods are provided for selectively not administering one or more vasopressin receptor agonist(s) to a subject, wherein said subject has an adverse response genotype in their vasopressin pathway associated gene sequence.
- vasopressin receptor agonist in the manufacture of a medicament for the treatment of an inflammatory condition, wherein the subjects treated have an improved response polymorphism in their vasopressin pathway associated gene sequence.
- vasopressin receptor agonist in the manufacture of a medicament for the treatment of an inflammatory condition, wherein the subjects treated do not have an adverse response polymorphism in their vasopressin pathway associated gene sequence.
- vasopressin receptor agonist in the manufacture of a medicament for the treatment of an inflammatory condition in a subset of subjects, wherein the subset of subjects have an improved response polymorphism in their vasopressin pathway associated gene sequence.
- vasopressin receptor agonist in the manufacture of a medicament for the treatment of an inflammatory condition in a subset of subjects, wherein the subset of subjects do not have an adverse response polymorphism in their vasopressin pathway associated gene sequence.
- a commercial package containing, as active pharmaceutical ingredient, use of a vasopressin receptor agonist, or a pharmaceutically acceptable salt thereof, together with instructions for its use for the curative or prophylactic treatment of an inflammatory condition in a subject, wherein the subject treated has an improved response polymorphism in their vasopressin pathway associated gene sequence.
- a commercial package containing, as active pharmaceutical ingredient, use of a vasopressin receptor agonist, or a pharmaceutically acceptable salt thereof, together with instructions for its use for the curative or prophylactic treatment of an inflammatory condition in a subject, wherein the subject treated does not have an adverse response polymorphism in their vasopressin pathway associated gene sequence.
- the method or use may further include determining the subject's APACHE II score as an assessment of subject risk.
- the method or use may further include determining the number of organ system failures for the subject as an assessment of subject risk.
- the subject's APACHE II score may be indicative of an increased risk when > 25. 2 or more organ system failures may be indicative of increased subject risk.
- the improved response genotype may be found at one or more of the following polymorphic sites: rsl8059; rs2771 1; rsl0051637; rsl410713; rs857240; rs857242; and rsl495027; or a polymorphic site in linkage disequilibrium thereto.
- the polymorphic site in linkage disequilibrium is selected from one or more of the following: rs2762; rslOO51637; rsl477364; rs7731592; rs7736466; rsl363974; rs2351010; rsl423357; rsl544777; rs2161548; rs38032; rs38034; rs38041 ; rs27436; rs27306; rs27307; rs27397; rs27659; rs27711 ; rs27290; rs38030; rs27294; rs27747; rs39602; rs248215; rs27302; rs2278018; rsl559355; rs3734015; rs4869315; rs2247650; rs2549781
- the improved response genotype may be selected from one or more of the following: rsl8059CT; rsl8059TT; rs2771 IGG; rsl0051637GA; rsl0051637AA; rsl410713AC; rsl410713AA; rs857240CC; rs857242CC; rsl495027CC; and rsl495027CT; or a polymorphic site in linkage disequilibrium thereto.
- the adverse response genotype which may be selected from one or more of the following: rsl8059CC; rs2771 IAA; rsl0051637GG; rsl410713CC; rs857240CT; rs857242AC; and rsl495027TT; or a polymorphic site in linkage disequilibrium thereto.
- the genotype of the polymorphic site in linkage disequilibrium may be selected from one or more of the polymorphic sites and corresponding genotypes set out in TABLES IB and ID.
- the subject having one or more improved response genotypes may be selectively administered the vasopressin receptor agonist.
- the subject having one or more adverse response genotypes may be selectively not administered the vasopressin receptor agonist.
- methods are provided for selecting a group of subjects for determining the efficacy of a candidate drug known or suspected of being useful for the treatment of an inflammatory condition, the method including determining a genotype at one or more polymorphic sites in a vasopressin pathway gene sequence for each subject, wherein said genotype is indicative of the subject' s ability to recover from the inflammatory condition and sorting subjects based on their genotype.
- the method may further include, administering the candidate drug to the subjects or a subset of subjects and determining each subject's ability to recover from the inflammatory condition.
- the method may further include comparing subject response to the candidate drug based on genotype of the subject.
- the polymorphic site may be selected from one or more of the following: rs 18059; rs27711; rs38041; rsl0051637; rsl410713; rs857240; rs857242; rsl0877970; rs3803107; and rsl495027; or a polymorphic site in linkage disequilibrium thereto.
- the polymorphic site in linkage disequilibrium may be selected from one or more of the following: rs2762; rslOO51637; rsl477364; rs7731592; rs7736466; rsl363974; rs2351010; rsl423357; rsl544777; rs2161548; rs38O32; rs38034; rs38041; rs27436; rs27306; rs27307; rs27397; rs27659; rs27711 ; rs27290; rs38O3O; rs27294; rs27747; rs39602; rs248215; rs27302; rs2278018; rs 1559355; rs3734015; rs4869315; rs2247
- the method may further include comparing the genotype determined with known genotypes, which are known to be indicative of a prognosis for recovery from the subject's type of inflammatory condition, or another inflammatory condition.
- the method may further include obtaining vasopressin pathway gene sequence information for the subject.
- the genotype may be determined using a nucleic acid sample from the subject.
- the method may further include obtaining the nucleic acid sample from the subject.
- the genotype may be determined using one or more of the following techniques: restriction fragment length analysis; sequencing; micro-sequencing assay; hybridization; invader assay; gene chip hybridization assays; oligonucleotide ligation assay; ligation rolling circle amplification; 5' nuclease assay; polymerase proofreading methods; allele specific PCR; matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectroscopy; ligase chain reaction assay; enzyme-amplified electronic transduction; single base pair extension assay; and reading sequence data.
- the genotype of the subject may be indicative of increased risk of death or organ dysfunction from the inflammatory condition.
- the subject may be critically ill and the genotype is indicative of a pro
- the genotype may include at least one of the following risk genotypes: rsl8059CT; rsl8059TT; rs27711GA; rs27711GG; rs38041GA; rs38041GG; rsl0051637GA; rslOO51637GG; rsl410713AA; rs857240CC; rs857242CC; rslO87797OCC; rs3803107TT; and rsl495027TT; or a polymorphic site in linkage disequilibrium thereto.
- the genotype may include at least one of the following risk alleles: rs3803107T; and rslO87797OC; or a polymorphic site in linkage disequilibrium thereto.
- the genotype of the subject may be indicative of decreased risk of death or organ dysfunction from the inflammatory condition.
- the subject may be critically ill and the genotype is indicative of a prognosis of mild cardiovascular or respiratory dysfunction.
- the genotype may include at least one of the following reduced risk genotypes: rsl8059CC; rs2771 IAA; rs38041AA; rsl0051637AA; rsl410713CC; rsl410713AC; rs857240TT; rs857240CT; rs857242AA; rs857242AC; rsl0877970TT; rslO87797OCT; rs3803107CC; rs3803107CT; rsl495027CC and rsl495027CT; or a polymorphic site in linkage disequilibrium thereto.
- the genotype may include at least one of the following reduced risk alleles: rs38O31O7C
- the genotype of the polymorphic site in linkage disequilibrium may be selected from one or more of the polymorphic sites and corresponding genotypes set out in TABLES IB and ID.
- the inflammatory condition may be selected from the group consisting of: sepsis, septicemia, pneumonia, septic shock, systemic inflammatory response syndrome (SIRS), Acute Respiratory Distress Syndrome (ARDS), acute lung injury, aspiration pneumonitis, infection, pancreatitis, bacteremia, peritonitis, abdominal abscess, inflammation due to trauma, inflammation due to surgery, chronic inflammatory disease, ischemia, ischemia-reperfusion injury of an organ or tissue, tissue damage due to disease, tissue damage due to chemotherapy or radiotherapy, and reactions to ingested, inhaled, infused, injected, or delivered substances, glomerulonephritis, bowel infection, opportunistic infections, and for subjects undergoing major surgery or dialysis, subjects who are immunocompromised, subjects on immunosuppressive agents, subjects with HIV/ AIDS, subjects with suspected endocarditis, subjects with fever, subjects with fever of unknown origin, subjects with cystic fibrosis, subjects with diabetes mellitus, subjects
- coli 0157:H7 malaria, gas gangrene, toxic shock syndrome, pre-eclampsia, eclampsia, HELLP syndrome, mycobacterial tuberculosis, Pneumocystic carinii, pneumonia, Leishmaniasis, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, Dengue hemorrhagic fever, pelvic inflammatory disease, Legionella, Lyme disease,
- Influenza A Epstein-Barr virus, encephalitis, inflammatory diseases and autoimmunity including Rheumatoid arthritis, osteoarthritis, progressive systemic sclerosis, systemic lupus erythematosus, inflammatory bowel disease, idiopathic pulmonary fibrosis, sarcoidosis, hypersensitivity pneumonitis, systemic vasculitis, Wegener's granulomatosis, transplants including heart, liver, lung kidney bone marrow, graft-versus-host disease, transplant rejection, sickle cell anemia, nephrotic syndrome, toxicity of agents such as OKT3, cytokine therapy, and cirrhosis.
- the inflammatory condition may be SIRS.
- the inflammatory condition may be sepsis.
- the inflammatory condition may be septic shock.
- the vasopressin receptor agonist may be vasopressin.
- two or more oligonucleotides or peptide nucleic acids of about 10 to about 400 nucleotides that hybridize specifically to a sequence contained in a human target sequence consisting of a subject's vasopressin pathway associated gene sequence, a complementary sequence of the target sequence or RNA equivalent of the target sequence and wherein the oligonucleotides or peptide nucleic acids are operable in determining the presence or absence of two or more polymorphism(s) or in their vasopressin pathway associated gene sequence selected from of the following polymorphic sites: rsl8059; rs2771 1 ; rs38041; rsl0051637; rsl410713; rs857240; rs857242; rsl0877970; rs3803107; and rsl495027; or one or more polymorphic sites in linkage disequilibrium thereto.
- two or more oligonucleotides or peptide nucleic acids selected from the group including of: (a) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO: 1 having a T at position 201 but not to a nucleic acid molecule including SEQ ID NO: 1 having a C at position 201 ; (b) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:1 having a C at position 201 but not to a nucleic acid molecule including SEQ ID NO: 1 having a T at position 201 ; (c) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:2 having a G at position 201 but
- an array of oligonucleotides or peptide nucleic acids attached to a solid support the array including two or more of the oligonucleotides or peptide nucleic acids as set out herein.
- composition including an addressable collection of two or more oligonucleotides or peptide nucleic acids, the two or more oligonucleotides or peptide nucleic acids selected from the oligonucleotides or peptide nucleic acids as set out herein.
- composition including an addressable collection of two or more oligonucleotides or peptide nucleic acids, the two or more oligonucleotides or peptide nucleic acids consisting essentially of two or more nucleic acid molecules set out in SEQ ID NO: 1-264 or compliments, fragments, variants, or analogs thereof.
- ancomposition including an addressable collection of two or more oligonucleotides or peptide nucleic acids, the two or more oligonucleotides or peptide nucleic acids consisting essentially of two or more nucleic acid molecules set out in TABLES 1C and ID or compliments, fragments, variants, or analogs thereof.
- the oligonucleotides or peptide nucleic acids described herein may further include one or more of the following: a detectable label; a quencher; a mobility modifier; a contiguous non-target sequence situated 5' or 3' to the target sequence or 5' and 3' to the target sequence.
- a computer readable medium including a plurality of digitally encoded genotype correlations selected from the vasopressin pathway associated gene SNP correlations in TABLE IE, wherein each correlation of the plurality has a value representing an ability to recover from an inflammatory condition and a value representing an indication of responsiveness to treatment with a vasopressin receptor agonist.
- the oligonucleotides or peptide nucleic acids may further include one or more of the following: a detectable label; a quencher; a mobility modifier; a contiguous non-target sequence situated 5' or 3' to the target sequence or 5' and 3' to the target sequence.
- the oligonucleotides or peptide nucleic acids may alternatively be of about 10 to about 400 nucleotides, about 15 to about 300 nucleotides.
- the oligonucleotides or peptide nucleic acids may alternatively be of about 20 to about 200 nucleotides, about 25 to about 100 nucleotides.
- the oligonucleotides or peptide nucleic acids may alternatively be of about 20 to about 80 nucleotides, about 25 to about 50 nucleotides.
- the genotype may be determined using a nucleic acid sample from the subject. Genotype may be determined using one or more of the following techniques: restriction fragment length analysis; sequencing; micro-sequencing assay; hybridization; invader assay; gene chip hybridization assays; oligonucleotide ligation assay; ligation rolling circle amplification; 5' nuclease assay; polymerase proofreading methods; allele specific PCR; matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectroscopy; ligase chain reaction assay; enzyme-amplified electronic transduction; single base pair extension assay; and reading sequence data.
- MALDI-TOF matrix assisted laser desorption ionization time of flight
- a determination of whether a site is in linkage disequilibrium (LD) with another site may be determined based on an absolute r value or D' value.
- D' value an absolute value for linkage disequilibrium
- a high degree of linkage disequilibrium may be represented by an absolute value for D' of > 0.6 or r 2 > 0.6.
- a higher degree of linkage disequilibrium may be represented by an absolute value for D' of > 0.7 or r 2 > 0.7 or by an absolute value for D' of > 0.8 or r 2 > 0.8.
- a high degree of linkage disequilibrium may be represented by an absolute value for D' of > 0.85 or r 2 > 0.85 or by an absolute value for D' of > 0.9 or r 2 > 0.9.
- Two or more oligonucleotides or peptide nucleic acids may include 3 or more; 4 or more; 5 or more; 6 or more; 7 or more; 8 or more; 9 or more; 10 or more; 1 1 or more; 12 or more; 13 or more; 14 or more; 15 or more; 16 or more; 17 or more; 18 or more; 19 or more; or 20 or more.
- Sequence variations may be assigned to a gene if mapped within 2 kb or more of an mRNA sequence feature.
- a sequence may extend many kilobases (kb) from a vasopressin pathway gene and into neighbouring genes, where the LD within a region is strong.
- LNPEP Leucyl aminopeptidase
- AVPRlA arginine vasopressin receptor
- AVPRlA arginine vasopressin receptor
- Vassopressin Receptor Agonist as used herein includes any vasopressin molecule, vasopressin derivative, vasopressin variant, vasopressin analogue, non-peptidyl analogues and any prodrug thereof, metabolite thereof, isomer thereof, combination of isomers thereof, or pharmaceutical composition of any of the preceding.
- Such agonists may be capable of binding to or interacting with a vasopressin receptor and initiating one or more of the types of responses typically produced by the binding of an endogenous vasopressin molecule to a vasopressin receptor (for example, AVPRlA, AVPRlB, AVPR2 and OXTR).
- Vasopressin receptor agonists may be used alone or in combination with other vasopressin receptor agonists or other medications. Vasopressin receptor agonists may be synthesized or purified. Examples of vasopressin receptor agonists capable of increasing blood pressure, include, but are not limited to, arginine vasopressin (AVP), lysine vasopressin (LVP), triglycil-lysine vasopressin (also known as Terlipressin or Glycopressin), Octapressin, Ornipressin, Desmopressin, Desmopressin acetate, Lypressin, Felypressin, and
- Vasopressin analogues may be 1 - 3 amino acids such as AIa-AVP, Ser-Ala-AVP, Thr-Ser-Ala-A VP (KALISZAN R. et al. Pharmacol Res Commun (1988) 20(5):377-381) or 3- beta- (2-thienyl)-L-alanine)-8-lysine-vasopressin and other similar analogues (Smith CW. Acta Pharmacol Toxicol (Copenhag) (1978) 43(3): 190-195). Examples of derivatives, variants, analogues or compositions etc.
- Vasopressin as used herein includes: Antidiuretic hormone; Argiprestocin; Arginine Vasopressin; Arginine oxytocin; Pitressin tannate; Arginine vasotocin; Vasotocin; Vasopressin, isoleucyl; 3-Isoleucyl vasopressin; l-[[19-amino-13-butan-2-yl-10-(2-carbamoylethyl)-7- (carbamoylmethyl)- 16-[(4-hydroxyphenyl)methyl]-6,9, 12,15,18-pentaoxo- 1 ,2-dithia-5,8, 11,14,17- pentazacycloicos-4-yl]carbonyl]-N-[l-(carbamoylmethylcarbamoyl)-4-guanidino-butyl]- pyrrolidine-2-carboxamide (IUPAC name).
- Vasopressin is a nine amino acid peptide (Cys-Tyr- Ile-Gln-Asn-Cys-Pro-Arg-Gly, cyclic 1-6 disulfide) secreted from the posterior pituitary and binds to receptors in blood vessels, the brain and distal or collecting tubules of the kidney to promote vasoconstriction or reabsorption of water back into the circulation.
- Vasopressin receptor targets include AVPRlA, AVPRlB, AVPR2 and OXTR.
- Vasopressin for example, is sold as PRESSYN ARTM by Ferring Inc., and also sold in various formulations as VASOPRESSIN by Ferring Inc., Sandoz Canada Inc.
- PITRESSINTM is sold by Warner-Lambert Company, Parke-Davis Division, as a synthetic injectable vasopressin (8- Arginine vasopressin). It is substantially free from the oxytocic principle and is standardized to contain 20 pressor units/mL. The solution contains 0.5% Chlorobutanol (chloroform derivative) as a preservative. Also, DIAPIDTM is sold as a nasal spray by Sandoz Inc.
- vasopressin is intended for use in the prevention of treatment of post-operative abdominal distension, dispelling of gas shadows in abdominal roentgenography and symptomatic control of diabetes insipidus.
- Genetic material includes any nucleic acid and can be a deoxyribonucleotide or ribonucleotide polymer in either single or double-stranded form.
- a “purine” is a heterocyclic organic compound containing fused pyrimidine and imidazole rings, and acts as the parent compound for purine bases, adenine (A) and guanine (G).
- a "Nucleotide” is generally a purine (R) or pyrimidine (Y) base covalently linked to a pentose, usually ribose or deoxyribose, where the sugar carries one or more phosphate groups.
- Nucleic acids are generally a polymer of nucleotides joined by 3 '-5' phosphodiester linkages.
- purine is used to refer to the purine bases, A and G, and more broadly to include the nucleotide monomers, deoxyadenosine-5' -phosphate and deoxyguanosine-5' -phosphate, as components of a polynucleotide chain.
- a "pyrimidine” is a single-ringed, organic base that forms nucleotide bases, cytosine (C), thymine (T) and uracil (U).
- pyrimidine is used to refer to the pyrimidine bases, C, T and U, and more broadly to include the pyrimidine nucleotide monomers that along with purine nucleotides are the components of a polynucleotide chain.
- a nucleotide represented by the symbol M may be either an A or C
- a nucleotide represented by the symbol W may be either an T/U or A
- a nucleotide represented by the symbol Y may be either an C or T/U
- a nucleotide represented by the symbol S may be either an G or C
- a nucleotide represented by the symbol R may be either an G or A
- a nucleotide represented by the symbol K may be either an G or TAJ.
- nucleotide represented by the symbol V may be either A or G or C
- a nucleotide represented by the symbol D may be either A or G or T
- a nucleotide represented by the symbol B may be either G or C or T
- a nucleotide represented by the symbol H may be either A or C or T.
- a "polymorphic site” or “polymorphism site” or “polymorphism” or “single nucleotide polymorphism site” (SNP site) or single nucleotide polymorphism” (SNP) as used herein is the locus or position with in a given sequence at which divergence occurs.
- a “polymorphism” is the occurrence of two or more forms of a gene or position within a gene (allele), in a population, in such frequencies that the presence of the rarest of the forms cannot be explained by mutation alone. The implication is that polymorphic alleles confer some selective advantage on the host.
- Preferred polymorphic sites have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population.
- Polymorphic sites may be at known positions within a nucleic acid sequence or may be determined to exist using the methods described herein. Polymorphisms may occur in both the coding regions and the noncoding regions (for example, promoters, introns or untranslated regions) of genes. Polymorphisms may occur at a single nucleotide site (SNPs) or may involve an insertion or deletion as described herein.
- SNPs single nucleotide site
- a "risk genotype” as used herein refers to an allelic variant (genotype) at one or more polymorphic sites within the vasopressin pathway gene (i.e. AVP, AVPRlA and LNPEP) sequences described herein as being indicative of a decreased likelihood of recovery from an inflammatory condition or an increased risk of having a poor outcome.
- the risk genotype may be determined for either the haploid genotype or diploid genotype, provided that at least one copy of a risk allele is present. Risk genotype may be an indication of an increased risk of not recovering from an inflammatory condition.
- Subjects having one copy (heterozygotes) or two copies (homozygotes) of the risk allele are considered to have the "risk genotype" even though the degree to which the subjects risk of not recovering from an inflammatory condition may increase, depending on whether the subject is a homozygote rather than a heterozygote.
- Such "risk alleles” or “risk genotypes” may be selected from the following: rsl8059CT; rsl8059TT; rs2771 1GA; rs27711GG; rs38041GA; rs38041GG; rslOO51637GA; rslOO51637GG; rsl410713AA; rs857240CC; rs857242CC; rsl0877970TT; rs38O31O7TT; and rsl495027CC; or a polymorphic site in linkage disequilibrium thereto.
- a “decreased risk genotype” as used herein refers to an allelic variant (genotype) at one or more polymorphic sites within the vasopressin pathway gene (i.e. AVP, AVPRlA and LNPEP) sequences described herein as being indicative of an increased likelihood of recovery from an inflammatory condition or a decreased risk of having a poor outcome.
- the decreased risk genotype may be determined for either the haploid genotype or diploid genotype, provided that at least one copy of a risk allele is present.
- Decreased risk genotype may be an indication of an increased likelihood of recovering from an inflammatory condition.
- Subjects having one copy (heterozygotes) or two copies (homozygotes) of the decreased risk allele are considered to have the "decreased risk genotype" even though the degree to which the subjects risk of not recovering from an inflammatory condition may increase, depending on whether the subject is a homozygote rather than a heterozygote.
- Such “decreased risk alleles” or “decreased risk genotypes” or “reduced risk genotypes” may be selected from the following: rsl8059CC; rs27711AA; rs38041AA; rsl0051637AA; rsl410713CC; rsl410713AC; rs857240TT; rs857240CT; rs857242AA; rs857242AC; rsl0877970TT; rslO87797OCT; rs3803107CC; rs3803107CT; rsl495027CC and rsl495027CT; or a polymorphic site in linkage disequilibrium thereto.
- IRG improved response genotype
- FRP improved response polymorphic variant
- AVP arginine vasopressin
- AVPRlA arginine vasopressin receptor IA
- LNPEP leucyl/cystinyl aminopeptidase
- LRAP leukocyte -derived aminopeptidase
- ARG adverse response genotype
- AVP arginine vasopressin
- AVPRlA arginine vasopressin receptor IA
- LNPEP leucyl/cystinyl aminopeptidase
- LRAP leukocyte- derived aminopeptidase
- a "clade” is a group of haplotypes that are closely related phylogenetically. For example, if haplotypes are displayed on a phylogenetic (evolutionary) tree a clade includes all haplotypes contained within the same branch.
- Haplotype The pattern of a set of markers along a chromosome is referred to as a "Haplotype". Accordingly, groups of alleles on the same small chromosomal segment tend to be transmitted together. Haplotypes along a given segment of a chromosome are generally transmitted to progeny together unless there has been a recombination event. Absence of a recombination event, haplotypes can be treated as alleles at a single highly polymorphic locus for mapping.
- haplotype is a set of alleles of closely linked loci on a chromosome that tend to be inherited together. Such allele sets occur in patterns, which are called haplotypes. Accordingly, a specific SNP or other polymorphism allele at one SNP site is often associated with a specific SNP or other polymorphism allele at a nearby second SNP site or other polymorphism site. When this occurs, the two SNPs or other polymorphisms are said to be in LD because the two SNPs or other polymorphisms are not just randomly associated (i.e. in linkage equilibrium).
- the detection of nucleic acids in a sample depends on the technique of specific nucleic acid hybridization in which the oligonucleotide is annealed under conditions of "high stringency" to nucleic acids in the sample, and the successfully annealed oligonucleotides are subsequently detected (see for example Spiegelman, S., Scientific American, Vol. 210, p. 48 (1964)).
- Hybridization under high stringency conditions primarily depends on the method used for hybridization, the oligonucleotide length, base composition and position of mismatches (if any).
- High-stringency hybridization is relied upon for the success of numerous techniques routinely performed by molecular biologists, such as high-stringency PCR, DNA sequencing, single strand conformational polymorphism analysis, and in situ hybridization.
- these aforementioned techniques are usually performed with relatively short probes (e.g., usually about 16 nucleotides or longer for PCR or sequencing and about 40 nucleotides or longer for in situ hybridization).
- the high stringency conditions used in these techniques are well known to those skilled in the art of molecular biology, and examples of them can be found, for example, in Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 1998.
- Oligonucleotides as used herein are variable length nucleic acids, which may be useful as probes, primers and in the manufacture of microarrays (arrays) for the detection and/or amplification of specific nucleic acids. Such DNA or RNA strands may be synthesized by the sequential addition (5'-3' or 3'-5') of activated monomers to a growing chain, which may be linked to an insoluble support. Numerous methods are known in the art for synthesizing oligonucleotides for subsequent individual use or as a part of the insoluble support, for example in arrays (BERNFIELD MR. and ROTTMAN FM. J. Biol. Chem.
- oligonucleotides are synthesized through the stepwise addition of activated and protected monomers under a variety of conditions depending on the method being used. Subsequently, specific protecting groups may be removed to allow for further elongation and subsequently and once synthesis is complete all the protecting groups may be removed and the oligonucleotides removed from their solid supports for purification of the complete chains if so desired.
- PNA protein nucleic acids
- PNA protein nucleic acids
- DNA/RNA DNA/RNA
- backbone structure of PNA does not inherently have a charge. Therefore, there is no electrostatic repulsion. Consequently, PNA has a higher ability to form double strands as compared with conventional nucleic acids, and has a high ability to recognize base sequences.
- PNAs are generally more robust than nucleic acids. PNAs may also be used in arrays and in other hybridization or other reactions as described above and herein for oligonucleotides.
- an "addressable collection” as used herein is a combination of nucleic acid molecules or peptide nucleic acids capable of being detected by, for example, the use of hybridization techniques or by any other means of detection known to those of ordinary skill in the art.
- a DNA microarray would be considered an example of an "addressable collection”.
- linkage refers to the co-inheritance of two or more nonallelic genes or sequences due to the close proximity of the loci on the same chromosome, whereby after meiosis they remain associated more often than the 50% expected for unlinked genes.
- a physical crossing between individual chromatids may result in recombination.
- Recombination generally occurs between large segments of DNA, whereby contiguous stretches of DNA and genes are likely to be moved together in the recombination event (crossover).
- regions of the DNA that are far apart on a given chromosome are more likely to become separated during the process of crossing-over than regions of the DNA that are close together.
- Polymorphic molecular markers like SNPs, are often useful in tracking meiotic recombination events as positional markers on chromosomes.
- Linkage Disequilibrium This sort of disequilibrium generally implies that most of the disease chromosomes carry the same mutation and the markers being tested are relatively close to the disease gene(s).
- SNPs can be useful in association studies for identifying polymorphisms, associated with a pathological condition, such as sepsis. Unlike linkage studies, association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families. In a SNP association study the frequency of a given allele (i.e. SNP allele) is determined in numerous subjects having the condition of interest and in an appropriate control group. Significant associations between particular SNPs or SNP haplotypes and phenotypic characteristics may then be determined by numerous statistical methods known in the art. Association analysis can either be direct or LD based. In direct association analysis, potentially causative SNPs may be tested as candidates for the pathogenic sequence.
- SNPs may be chosen at random over a large genomic region or even genome wide, to be tested for SNPs in LD with a pathogenic sequence or pathogenic SNP.
- candidate sequences associated with a condition of interest may be targeted for SNP identification and association analysis. Such candidate sequences usually are implicated in the pathogenesis of the condition of interest.
- candidate sequences may be selected from those already implicated in the pathway of the condition or disease of interest. Once identified, SNPs found in or associated with such sequences, may then be tested for statistical association with an individual's prognosis or susceptibility to the condition.
- VNTRs variable number tandem repeats
- STRs short tandem repeats
- linkage disequilibrium is the occurrence in a population of certain combinations of linked alleles in greater proportion than expected from the allele frequencies at the loci. For example, the preferential occurrence of a disease gene in association with specific alleles of linked markers, such as SNPs, or between specific alleles of linked markers, are considered to be in LD.
- This sort of disequilibrium generally implies that most of the disease chromosomes carry the same mutation and that the markers being tested are relatively close to the disease gene(s). Accordingly, if the genotype of a first locus is in LD with a second locus (or third locus etc.), the determination of the allele at only one locus would necessarily provide the identity of the allele at the other locus. When evaluating loci for LD those sites within a given population having a high degree of linkage disequilibrium (i.e. an absolute value for r 2 > 0.5) are potentially useful in predicting the identity of an allele of interest (i.e. associated with the condition of interest).
- a high degree of linkage disequilibrium may be represented by an absolute value for r 2 > 0.6.
- a high degree of linkage disequilibrium may be represented by an absolute value for r 2 > 0.7 or by an absolute value for r 2 > 0.8.
- a high degree of linkage disequilibrium may be represented by an absolute value for r 2 > 0.85 or by an absolute value for r 2 > 0.9.
- two SNPs that have a high degree of LD may be equally useful in determining the identity of the allele of interest or disease allele. Therefore, we may assume that knowing the identity of the allele at one SNP may be representative of the allele identity at another SNP in LD. Accordingly, the determination of the genotype of a single locus can provide the identity of the genotype of any locus in LD therewith and the higher the degree of linkage disequilibrium the more likely that two SNPs may be used interchangeably.
- the determination of the genotype at rs 18059 will provide the identity of the genotype at rs2762 or any other locus in "linkage disequilibrium" therewith. Particularly, where such a locus is has a high degree of linkage disequilibrium thereto.
- LD is useful for genotype-phenotype association studies. For example, if a specific allele at one SNP site (e.g. "A") is the cause of a specific clinical outcome (e.g. call this clinical outcome "B") in a genetic association study then, by mathematical inference, any SNP (e.g. "C") which is in significant LD with the first SNP, will show some degree of association with the clinical outcome. That is, if A is associated ( ⁇ ) with B, i.e. A-B and C-A then it follows that C-B. Of course, the SNP that will be most closely associated with the specific clinical outcome, B, is the causal SNP - the genetic variation that is mechanistically responsible for the clinical outcome. Thus, the degree of association between any SNP, C, and clinical outcome will depend on LD between A and C.
- LD helps identify potential candidate causal SNPs and also helps identify a range of SNPs that may be clinically useful for prognosis of clinical outcome or of treatment effect. If one SNP within a gene is found to be associated with a specific clinical outcome, then other SNPs in LD will also have some degree of association and therefore some degree of prognostic usefulness.
- TABLE IA Numerous sites have been identified as polymorphic sites in the vasopressin pathway associated genes (see TABLE IA). Furthermore, the polymorphisms in TABLE IA are linked to (in LD with) numerous polymorphism as set out in TABLE IB below and may also therefore be indicative of subject prognosis.
- NA as used above indicates that the LD allele with the information currently available to the inventors could not with any confidence be assigned without further routine analysis, due to the lack of suitable information currently available regarding the corresponding allele designations. However, it would be well within the abilities of a person of skill in the art to make LD allele designations for the NA polymorphisms using routine analysis.
- a haplotype of vasopressin pathway associated genes can be created by assessing polymorphisms in vasopressin pathway-associated genes in normal subjects using a program that has an expectation maximization algorithm (i.e. PHASE).
- a constructed haplotype of vasopressin pathway associated genes may be used to find combinations of SNPs that are in LD with the tag SNPs (tSNPs) identified herein. Accordingly, the haplotype of an individual could be determined by genotyping other SNPs or other polymorphisms that are in LD with the tSNPs identified herein.
- Single polymorphic sites or combined polymorphic sites in LD may also be genotyped for assessing subject response to vasopressin receptor agonist treatment.
- the numerical designations of the positions of polymorphisms within a sequence are relative to the specific sequence. Also the same positions may be assigned different numerical designations depending on the way in which the sequence is numbered and the sequence chosen, as illustrated by the alternative numbering of the equivalent polymorphism (rs3803107), whereby the same polymorphism identified C/T at position 3536 of the NM_000706.3 (GI:33149325), which corresponds to position 201 of SEQ ED NO:9.
- sequence variations within the population such as insertions or deletions, may change the relative position and subsequently the numerical designations of particular nucleotides at and around a polymorphic site.
- Polymorphic sites in SEQ ED NO: 1-10 are identified by their variant designation (i.e. M, W, Y, S, R, K, V, B, D, H or by "-" for a deletion, a "+”or for example "G” etc. for an insertion).
- Polymorphic sites in SEQ ED NO: 11-264 are identified by their allelic change (i.e. A, C, G, T or by "-" for a deletion, a "+”or for an insertion).
- the "rs” numbers are the NCBI rsSNP ID form.
- TABLE ID below shows the flanking sequences for a selection of vasopressin pathway associated gene SNPs in LD with the tagged SNPs in TABLE 1C, providing their rs designations and corresponding SEQ ID NO designations.
- a SNP in LD is also an htSNP it only occurs in TABLE 1C above.
- Each SNP is at position 200 of the flanking sequence (unless otherwise indicated) and is underlined.
- allelic pair i e. the two alleles of a given gene
- ⁇ "gene” is an ordered sequence of nucleotides located in a particular position on a particular chromosome that encodes a specific functional product and may include untranslated and untranscribed sequences in proximity to the coding regions (5' and 3' to the coding sequence). Such non-coding sequences may contain regulatory sequences needed for transcription and translation of the sequence or introns etc. or may as yet to have any function attributed to them beyond the occurrence of the SNP of interest.
- a “genotype” is defined as the genetic constitution of an organism, usually in respect to one gene or a few genes or a region of a gene relevant to a particular context (i.e. the genetic loci responsible for a particular phenotype).
- a "phenotype” is defined as the observable chaiacters of an organism In gene association studies, the genetic model at a given locus can change depending on the selection pressures (i e , the
- the model at rs 1410713 changed between the risk of death claims (AA versus AC/CC) and the vasopressin IRP claims (AA/AC veisus C C) This is a case of the same outcome variable (survival) tollow ing a different genetic model in diffeient environments (i e . no vasopressin treatment versus vasopressin treatment)
- Hemoglobin S results in abnoimal sitkle-shaped ied blood cells w hich lead to anemia and other serious complications including death In the absence of malana.
- a gene association study w ith the HBB gene would suggest a codominant model (surv ival(BB) > survival (BS) > surv ival (SS))
- BS survival
- SS surv ival
- a gene association study w ith the HBB gene would suggest a heterozygote adv antage model (survival(BB) ⁇ surv ival(BS) >
- ⁇ single nucleotide polymoiphism " ' (SNP) occurs at a polymorphic site occupied by a single nucleotide, w hich is the site of vai ution between allelic sequences The site is usually pieceded by and followed by highly conserved sequences of the allele (e g , sequences that vary in less than
- a single nucleotide polymoiphism usually arises due to substitution of one nucleotide for another at the polymorphic site
- a "transition” is the teplacement of one purine by another pu ⁇ ne oi one pyi imidine by another pynmidine
- a "tiansvei sion” is the replacement of a pur ne by a pynmidine oi v ice veisa
- Single nucleotide poly morphisms can also a ⁇ se fiom a deletion (represented by "-" oi "del") of a nucleotide oi an
- an insertion or deletion w ithin a given sequence could alter the relative poMtion and theiefore the position number of another polymorphism w ithin the sequence
- an insertion or deletion may by some definitions not qualify as a SNP as it may involve the deletion of or insertion of more than a single nucleotide at a given position, as used heiein such polymorphisms are also called SNPs as the y generall) result from an insertion or deletion at a single site w ithin a given sequence
- systemic inflammatory response syndrome or (SIRS) is defined as including both septic 1 1 e 5 sepsis or septic shock) and non-septic systemic inflammatory response (i e post operative)
- SIRS is further defined according to ACCP (American College of Chest Physicians) guidelines as themony of two 01 moie of A) temperature > 38 0 C or ⁇ 36"C, B) heart rate > 90 beats per minute, C) respnatory rate > 20 breaths per minute, or PaCCK ⁇ M mm Hg oi the need for mechanical ventilation, and D) white blood cell count > 12,000 per mm or ⁇ 4.000 mm
- ACCP American College of Chest Physicians
- Sepsis is defined as the presence of at least two “SIRS” criteria and known or suspected source of infection Septic shock was defined as sepsis plus one new organ failuie by Brussels c ⁇ tei ia I s plus need foi vasopiessor medication or v asopressin ieceptor agonist
- Subject outcome or prognosis as used herein refers the ability of a subject to recover from an inflammatoiy condition and may be used o determine the efficacy of a tieatment legimen, foi example the administration of a vasopressin ieceptor agonist
- An inflammatoiy condition may be
- renin-up consisting of sepsis, septicemia, pneumonia, septic shock, systemic inflammatoiv iesponse syndrome (SIRS).
- SIRS systemic inflammatoiv iesponse syndrome
- ARDS Acute Respiratory Distiess Syndrome
- aspiiation pneumonitis infection, pancreatitis, bacteremia, pe ⁇ tonitis, abdominal abscess, inflammation due to trauma, inflammation due to suigery, chronic inflammatory disease, ischemia, ischemia-reperfusion injury of an organ or tissue, tissue damage due to disease, tissue
- subjects w ho are immunocompromised subjects on immunosuppiessi ⁇ e agents, subjects w ith HIV/AIDS, subjects w ith suspected endocaiditis, subjects w ith fever, subjects w ith fevei of unknown ongin. sublets w ith cystic fibrosis, subjec ts
- ATN aciitt tubulai necrosis
- subjects w ith bronchiectasis subjects w ith chronic obstructive lung disease, chionic bronchitis, emphysema ot asthma, subjects w ith febrile neutropenia, subjects w ith meningitis, subjects w ith septic arthi itis, subjects w ith unnary tract infection, subjects w ith necrotizing fasciitis, subjects w ith other Hispected Group A streptococcus infection, subjects who ha ⁇ e had a splenectomy, subjects w ith recurrent or suspected enteiococcus infection, other medical and suigical conditions associated w ith increased risk of infection, Gram positive sepsis.
- Gram negative sepsis culture negative sepsis, fungal sepsis, meningococcemia, post-pump syndrome.
- s cardiac stun syndrome myocardial infarction, stioke, congestive heart failure, hepatitis, epiglottitis.
- E coli 0157 H7. malaria gas gangiene, toxic shock s> ndrome, pre-eclampsia, eclampsia.
- HELLP syndiome mycobacte rial tuberculosis, Pneumocystis carina pneumonia, pneumonia.
- Leishmaniasis hemolytic uremic syndrome/thrombotic thrombocytopenic purpuia, Dengue hemoirhagic fever, pelvic inflammatory disease, Legionella, Lyme disease. Influenza A,
- Wegener's gianulomatosis tiansplants including heart, liver, lung kidney bone mauow, graft-veisus-host disease, tiansplant rejection, sickle cell anemia,
- I S nephtotic syndiome toxicity of agents such as OKTl, cytokine theiapy, and ciirhosis
- APACHE IT' score is defined as Acute Physiology And Chioni; Health Evaluation and herein was calculated on a daily 0 basis from taw clinical and laboiatoiy vai iables Vincent et al (Vincent JL Feireira F Moreno R 2000 Cut Caie Clin 16 153-366) summarize APACHE scoie as follows "Fust developed in 1981 by Knaus c t al .
- the AP ⁇ CHE scoie has become the most commonly used sutvival prediction model in ICUs worldwide
- the APACHE II score a rev ised and simplified version of the original prototype, uses a point scoie based on mi ial values of 12 ioutine physiologic measures, age. ind
- a "Brussels score” score is a method for evaluating oigan dysf unction as compared to a baseline If the Brussels scoie is 0 (i e modeiate, severe, oi extieme). then oigan failure was recoided as present on that particular day (see TABLE 2A below)
- DAF organ failuie
- a pulmonary capillary wedge pressure less than 18 mm Hg The severity of acute lung injury is assessed by measuring days alivt and fiee of acute lung injury over a 28-day observation penod Acute lung injury is iecorded as piesent on each day that the person has modeiate, severe or extreme dysfunction as defined in the Brussels score Days alive and fiee of acute lung injury is calculated as the number of days af ter onset of acute lung injuiy that a subject is alive and free of acute lung injuiy over a def ined obsei vation period (28 days) Thus, a low ei score foi days alive and free of acute lung injury indicates more seveie acute lung in)uiy The reason that days alive and free of acute lung injuiy is
- I 1 S piefeiable to simplyumblence oi absence of acute lung injury is that acute lung injury has a hi gh acute moitality and early death (w ithin 28 days) precludes calculation of the presence oi absence of acute lung injuiy in dead subjects
- the cardiovasculai, ienal, neuiologic hepatic and coagulation dysfunction were similarly def ined as present on each day that the person had moderate seveie oi extreme dysfunction a> defined by the Brussels score Days alive and fiee of
- One aspect of the invention may involve the identification of subjects oi the selection ot subjects that aie either at nsk of developing and inflammatory condition or the identif ication of subject ⁇ s who already have an inflammatoiy condition
- subjects who have undeigone major surgeiy or scheduled foi oi contemplating major surgery may be considered as being at i isk of developing an inflammatoiy condition
- subjects may be detei mined as ha ⁇ ing an inflammatory condition using diagnostic methods and clinical evaluations known in the medical aits An inflammatory condition.
- ma> be selected from the gioup consisting of sepsis, septicemia.
- SIRS systemic inflammatory iesponse syndiome
- ARDS Acute Respiratory Distiess Syndrome
- ⁇ failure hepatitis, epiglottitis, E coll 0157 H7. malaria, gas gangrene, toxic shock syndrome, preeclampsia eclampsia, HELLP syndrome, mycobacterial tuberculosis, Pneumocystis cai inii pneumonia, pneumonia.
- Leishmaniasis hemolytic uremic syndiome/thrombotic thiombocytopenic meme memea. Dengue hemorrhagic fever, pelvic inflammatoiy disease, Legionella, Lyme disease, Influenza ⁇ , Epstem-Barr v n us, encephalitis, inflammatory diseases and autoimmunity including
- genetic sequence information may be obtained from the subject or alternatively genetic sequence information may already have betn obtained horn the subject For example, a subject may have already provided a biological sample
- Genetic sequence information may be obtained in numeious diffeient ways and may involve the collection of a biological sample that contains genetic material, particularly, genetic matenal containing the sequence oi sequences of interest Many methods are known in the art for collecting biological samples and ex racting genetic matei ial from those samples Genetic
- DNA ma> be isolated fiom a biological sample when first the sample is lv, sed and then the DNA is sepaiated horn the lysate according to any one of a variety of multi-step piotocols. which can take varying lengths of time DNA isolation methods may involve the use of phenol (Sambrook. J et al ,
- Othei methods for DNA isolation utilize non-coirosive chaotropic agents
- These methods which die based on the use of guanidine salts, uiea and sodium iodide, involve lysis of a biological sample in a chaotropic aqueous solution and subsequent piecipitation of the crude DNA fraction w ith a lowei alcohol
- the final pot ification of the precipitated, ciude DNA f raction can be achieved by any one of several methods, including column chromatography (Analects, ( 1994) VoI
- RT-PCR Reverse Tiansc ⁇ ption Polymerase Chain Reaction
- PCR Polymerase Chain Reaction
- TMA Tiansc ⁇ ption Mediated Amplification
- LCR Ligase chain reaction
- NASBA Nucleic Acid Sequence Based Amplification
- othei methods know n in the art, and then furthei analyzed to detect or determine the presence or absence of one oi more polymoi phisms or mutations in the sequence of mteiest, provided that the genetic matei ial obtained contains the sequence of interest Particulai ly.
- a person may be interested in determining theernence oi absence of a mutation in a uisopiessin pathway associated gene sequence, as
- sequence of interest tnaj also include othei mutations, oi may also contain some of the sequence surrounding the mutation of interest
- Detection oi determination of a nucleotide identity, or the presence of one or tnoie single nucleotide polymorphism(s) may be accomplished by any one of a number methods or assays known in the ait Many DNA typing methodologies are useful for use in the detection of SNPs
- the majority of SNP genotyping ieactions or assays can be assigned to one of foui broad groups (sequence-specific hybridization, primer extension, oligonucleotide ligation and invasive clea ⁇ age) Fuithermore, there are numerous methods for analyzing/detecting the products of each 5 type of reaction (for example, fluorescence luminescence, mass measurement, electrophoresis, etc ) Furtheimore. reactions can occur in solution or on a solid support such as a glass slide, a chip, a bead, etc
- sequence-speciiic hybridization involves a hybridization probe, which is capable of 10 distinguishing between two DNA taigets differing at one nucleotide position by hybndization
- primer extension ieactions i e mini sequencing, nucleotide-specific extensions, oi simple PCR amplification
- sequence discrimination ieactions For example, in mini sequencing a pnmer anneals to its taiget DNA immediately upstieam of the SNP and is extended 25 w ith a single nucleotide complementary to lhe polymoiphic site Wheie the nucleotide is not complementaiy, no extension occuis
- Oligonucleotide ligation assays lequire two sequence-specific piobes and one common ligation piobe per SNP
- the common ligation probe hybridizes adjacent to a sequence-specific probe and W when there is a peifect match of the appiopnate sequence-specific probe, the ligase joins both the sequence-specific and the common probes Where there is not a perfect match the ligase is unable to join the sequence-specific and common piobes
- Piobes used in hybndization can include double-stranded DNA, single-stranded DNA and RNA oligonucleotides, and peptide nucleic acids Hybndization methods for the identification of single nucleotide polymoiphisms oi othei mutations involving a few nucleotides aie described in the U S Pat 6.270,961 , 6.025, 136, and 6,872.530 Suitable hybridization probes for use in accordance
- an invasive cleavage method lequnes an oligonucleotide called an InvaderTM piobe and sequence-specific piobes to anneal to the target DNA w ith an overlap of one nucleotide
- sequence-specific probe is complementary to the polymorphic base
- oveilaps of the !' end of the invader oligonucleotide foim a facilitatorcture that is lecognized and cleaved by a Flap 0 endonuclease releasing the 5' arm of the allele specific probe
- 5' exonutlease activity or TaqManTM assay is based on the 5' nuclease activity of Taq polymeiase that displaces and cleaves the oligonucleotide probes hybridized to the taiget DNA generating a fluorescent signal It is necuney to have two probes that differ at the
- one probe is complementary to the "noimal' sequence and the other to the mutation of interest
- These piobes have diffeient fluoiescent dyes attached to the 5' end and a quenchei attached to the T end when the piobes aie intact the quencher internets w ith the fluorophor bv fluoiescence resonance eneigy tiansfer (FRET) to quench the fluorescence of tht piobe Din ing the PCR annealing step
- FRET fluorophor bv fluoiescence resonance eneigy tiansfer
- the hybridization probes hybridize to target DNA
- the 5' fluoiescent dye is cleaved by the 5' nuclease activity of Taq polymeiase, leading to an inciease in fluorescence of the ieporter dve Mismatched probes are displaced w ithout fiagmentation
- Theistnce of a mutation in a sample is determined by measu
- the Illumina Golden Gate 1 M Assay uses a ⁇ ombined oligonucleotide ligation assay/ allele-speufic hybndization appioach (SHEN R et til Mut.it Res 200 ⁇ 573 70-82)
- SHEN R et til Mut.it Res 200 ⁇ 573 70-82 The first series of steps inv olve the hybridization of three oligonucleotides to a set of specific target SNPs, two ol these are fluorescently-labelled allele-specihc oligonucleotides (ASOs) and the thud a locus-specific oligonucleotide (LSO) binding 1 -20 bp dow nstieam of the ASOs
- a second series of steps involve
- I S Mutation detection methods may include but aie not limited to the following
- RFLP Restriction Fragment Length Polymoi phism
- Maxam-Gilbert technique foi sequencing involves the specific chemical cleavage of terminally labelled DNA
- four samples of the same labeled DNA are each subjected to a diffeient chemical ieaction to effect preferential cleavage of the DNA molecule at one or two nucleotides of a specific base identity
- the conditions aie adjusted to obtain only partial cleavage.
- each sample contains DNA fiagments of different lengths, each of which ends w ith the same one 01 two ot the four nucleotides In particular in one sample each fragment ends w ith a C, in another sample each fiagment ends w ith a C or a T, in i third sample each ends w ith a G, and in a fourth sample each ends w ith an A or a G
- each fragment ends w ith a C ends w ith the same one 01 two ot the four nucleotides
- each fragment ends w ith a C in another sample each fiagment ends w ith a C or a T, in i third sample each ends w ith a G, and in a fourth sample each ends w ith an A or a G
- leverse transcriptase w ith dideoxx nucleotides have been used to sequence encephalomyocaiditis v uus RNA (ZIMMERN D and KAESBERG P Pioc Natl Acad Sci USA ( 1978) 75(9) 4257-4261 ) MILLS DR and KRAMER FR (Proc Natl Acad Sci USA ( 1979) 76( 5) 2232-2235) desci ibe the use ol Q ⁇ ieplicase and the nucleotide analog inosine foi sequencing RNA in a chain-termination mechanism Diiect chemical methods for sequencing
- Othei methods include those of Donis-Keller i t ai ( 1977. Niicl Acids Res 4 2527-2538). SIMONCSITS A i t al (Natuie ( 1977) 269(5611 ) 811-816), AXELROD VD et al (Nucl Acids Res ( 1978 ) 5( 10) 1 ⁇ 49-1561).
- Nucleic acid sequences can also be read by stimulating the natural i() tluoiesce of a cleaved nucleotide w ith a laser while the single nucleotide is contained in a fluoiescence enhancing matr ix (U S Pat # ⁇ ,674 743), In a mini sequencing reaction, a primer that anneals to taigct DNA adjacent to a SNP is extended by DNA polymerase w ith a single nucleotide that is complementary to the polymoiphic site This method is based on the high accuiacy of nucleotide incorporation by DNA poly merases There are diffeient technologies for analyzing the primer extension products For example, the use of labeled or unlabeled nucleotides, ddNTP combined w ith dNTP or only
- S Piobes used in hybridization can include double-stranded DNA, single-stranded DNA and RNA oligonucleotides, and peptide nucleic acids
- Hyb ⁇ dization methods for the identification of single nucleotide polymorphisms or othei mutations involving a few nucleotides are desci ibed in the U S Pat 6.270,961 , 6,025, 1 16, and 6.872,530
- Suitable hybridization probes for use in accoi dance w ith the invention include oligonucleotide ⁇ and PNAs from about 10 to about 400 nucleotides, 10 alternatively from about 20 to about 200 nucleotides, or from about 10 to about 100 nucleotides in length
- TDI-FP fluoiescent polarization-detection
- Oligonucleotide ligation assay is based on ligation of probe and detectoi oligonucleotides annealed to a polymerase chain ieaction amplicon strand w ith detection by an enzyme immunoassay (VILLAHERMOSA ML J Hum Vnol (2001 ) 4(5) 238-48, ROMPPANEN EL 20 Scand J Clin Lab Invest (2001 ) 61 (2) 123A IANNONE MA et al Cytometry (2000) 39(2) 131 - 40),
- Ligation-Rolling Ciicle Amplification has also been successfully used for genotyping single nucleotide polymoi phisms as desciibed in QI X et al Nucleic Acids Res (2001 ) 2s 29(22) E l 16,
- 5' nuclease assay has also been successfully used for genotyping single nucleotide polymoiphisms (AYDIN A et cil Biotechniques (2001 ) (4) 920-2. 924, 926-8 ),
- Matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectroscopy is also usef ul in the genotyping single nucleotide polymoi phisms through the analysis of crosequencing products (HAFF LA and SMIRNOV IP Nucleic Acids Res ( 1997) 2"S( 18) 3749- 5 O, HAFF LA and SMIRNOV IP Genome Res ( 1997) 7 178-388, SUN X et al Nucleic Acids Res (2000) 28 I O c68, BRAUN A et al Clin Chem ( 1997) 43 1 151 - 1 1 58.
- Sequence-specific PCR methods have also been successfully used for genotyping single nucleotide I S polymorphisms (HAWKINS JR et al Hum Mutat (2002) 19(5) 543-553)
- SSCP Single- Stranded Confoi manorial Polymorphism
- CFLP Cleavase Fragment Length Polymoi phism
- obtaining may involve retrieval 20 of the subjects nucleic acid sequence data ( foi example horn a database), followed by determining or detecting the identity of a nucleic acid oi genotype at a polymoiphic site by reading the subject ' s nucleic acid sequence at the one oi moie polymorphic sites
- polymorphisms in vasopressin pathway associated gene sequences are used to pi edict a subject's iesponse to v asopiessin ieceptor agonist tieatment
- Methods foi predicting a subject's iesponst to vasopressin ieceptor agonist tieatment may be useful in making decisions regaiding the M) administration of vasopiessin ieceptor agonist
- An improved response may include an improvement subsequent to administration of said therapeutic agent, whereby the subject has an increased likelihood of survival, reduced likelihood of organ damage or organ dysf unction (Brussels scoie), an improved APACHE II scoie, days alive and free of pressors, inotiopes. and ieduced systemic dysfunction (cardiovascular, lespnatory, ⁇ entilation, cential neivous system, coagulation [INR> 1 5
- sequence information or genotype information may be obtained from a subject w herein the sequence information contains one or more polymorphic sites in a vasopressin pathway associated gene sequence Also, as prev iously desci ibed the sequence identity of one or more poly morphisms in a vasopressin pathway associated gene sequence of one or more subjects
- subject iesponse to administration of vasopressin ieceptor agonist may be assessed as described above Foi example, the APACHE II scoi ing system or the Brussels score may be used to assess a subject's iesponse to treatment by compai ing subject scores before and after treatment
- subject response may be correlated w ith the sequence identity of one oi more polv moiphism(s)
- the correlation of subject iesponse may fuither include statistical analysis of subject outcome scoics and poly moi phism(s) foi a number of subjects
- An improved iesponse may include an unpiovement subsequent to administiation of said therapeutic agent, w hereby the subject has an inci eased likelihood ofenteval. reduced likelihood of oigan damage or oigan dysfunction (Brussels scoie). an impi oved APACHE II score, days alive and free of picssors, inotiopes. and reduced systemic dysfunction (cardiovasculai, respnatoiy, ventilation,
- sequence infoi mation oi genotype information may be obtained fiom a subject w heiein the sequence information contains one or more single nucleotide polymorphic sites in AVP.
- AVPRl A LNPEP or LRAP sequences Also, as previously described the sequence M) identity ot one or more single nucleotide polymoiphisms in the AVP, AVPRl A oi LNPEP sequences ot one or moie subjects may then be detected or detei mined Fuithermoie, subject outcome or piognosis may be assessed as described above, foi example the APACHE II scoring system or the Brussels scoie may be used to assess subject outcome or prognosis by compai ing sub
- ICU Intensive Care Unit
- SPH ICU St Paul's Hospital
- the seventy of cardiovascular dysfunction was assessed by measuring days alive and fiee ot caidiovasculai dysfunction ovei a 28-day observation period Days alive and free of caidiovascular dysfunction was calculated as the numbei of days after inclusion that a patient was alive and fiee of cardiovascular dysfunction over 28 days Thus, a lowei score for days alive and fiee of caidiovascular dysfunction indicates moie caidiov ascular dysfunction The ieason that
- caidiov asculai dysfunction I ⁇ days alive and hee of caidiov asculai dysfunction is pieferable to simplyfeednce or absence oF caidiov ascular dysfunction is that seveie sepsis has a high acute moitahty so that early death (w ithin 28 days) precludes calculation of thepsychnce or absence of cardiov ascular dysfunction in dead subjects Oigan dysfunction has been evaluated in this way in observ ational studies (Russell J A t t ⁇ l Cut Care Med (2000) 28( 10) 3405 1 1 ) and in landomized controlled trials of new
- vasopressor support To furthei evaluate cardiovascular, respiratory, and ienal function we also recorded, dunng each 24 hour penod. vasopressor support, mechanical ventilation, and renal support, lespectively
- IS Vasopressoi use was defined as dopamine > 5 ⁇ g/kg/min or any dose of norepinephrine, epinephrine, v asopressin, oi phenylephrine
- Mechanical ventilation was defined as need for intubation and positive anway pressure (i e T- piece and mask ventilation were not considered ventilation)
- Renal support was defined as hemodialysis pei itoneal dialysis, or any continuous renal support mode (e g continuous veno-venous hemodialysis)
- SIRS ciitei ia As a cumulative measuie of the severity of SIRS the presence of two, three or foui of the SIRS ciitei ia was scoied each day over the 28-da/ obseivation penod SIRS was considered present w hen subjects met at least two of tour SIRS cntei ia
- Baseline characte ⁇ stics foi the Biological Plausibility cohoit included age in years. 7c males Tsmoket s, r f diabetes, c /c hypertension, ejection fraction, bypass time, clamp time and aprotinin Outcome vai tables measured in the Biological Plausibility cohoit included Granulocyte colony stimulating factor (GCSF), Interleukin 10 (ILl O), Intel leukin receptoi I a (IL I ra), Inerukin 6 (IL6), Intel leukin 8 (IL8) and Monocyte Chemoattiactant Protein 1 (MCPl )
- GCSF Granulocyte colony stimulating factor
- ILl O Interleukin 10
- IL I ra Intel leukin receptoi I a
- IL6 Intel leukin 6
- IL8 Intel leukin 8
- MCPl Monocyte Chemoattiactant Protein 1
- genotype data was queried from the International HapMap Project t vv vv w hapmap org) and Perlegen Sciences Inc (www perlegen com) to select a set of tag SNF's
- tSNPs in the LNPEP, AVP and AVPR l A regions each hav ing a minor allele frequency (MAF) greater than 0 05
- LD pairw ise linkage disequilibrium
- haplotype SEPHENS M et al Am J Hum Genet (2001 ) 68 978-989. and EXCOFFIER L and SLATKIN M MoI Biol Evol ( 1995) 12(3) 921 -927) and haplotype block (HAWLEY ME and
- DNA samples were transfe ⁇ ed to 1 5 ⁇ iL cr>otubes, bar coded and ci oss-i eferenced w ith a unique patient numbei and stored at -8O 0 C
- the AVP, AVPR l A. LNPEP and LRAP genes are central to the action of vasopressin given that ⁇ asopiessin induces vasoconstnction by signaling through the AVPR l A ieceptor and that vasopiessin activ ity is inhibited when cleaved by LNPEP
- Similar protein homology between LNPEP and LRAP suggest that these two genes aiose through an ancient gene duplication event (DANCHIN E et til , Immunol Re ⁇ (2004) 198 216-332) This homology and the observation o ⁇ an extended linkage disequilibrium (LD) block throughout the LRAP and LNPEP region (HapMap
- LNPEP Leucyl/Cystinyl Aminopeptidase
- Table 3 4 and Table 3 5 show 28-day sui vival and oigan dysfunction data by LNPEP is l 8059 genotype for vasopiessin-treated and contiol subjects respectively
- Table 1 6 show s the dif ieiences in suiv ival and measures of oigan dysfunction between by LNPEP is 18059 genotype
- LNPEP leucyl/cystinyl aminopeptidase
- LNPEP leucyl/cystinyl ammopeptidase
- LNPEP leucv/1/cystinyl aminopeptidase
- I s i s2771 1 can be used to pi edict iesponse to vasopressin in subjects w ith septic shock using 28-day surviv al and measures of organ dysfunction as outcome vanables Of 103 vasopressin-treated and 103 matched-contiol subjects w ith septic shock.
- 70 and 81 weie iespectively genotyped tor LNPEP rs2771 1
- Baseline characteristics for subjects w ith genotypes are show n in Table 3 8 and Table ⁇ 9
- LNPEP i s2771 1 is in linkage w ith, for example.
- Baseline chaiacte ⁇ stics ot a group of Caucasian septic-shock contiol subjects by LNPEP rs277 1 1 genotype
- Tables 3 10, 1 1 1 and 3 12 contain 28-day survival and organ dysfunction data for septic-shock subjects genotyped for LNPEP rs2771 1
- vasopressin-treated subjects w ith the LNPEP rs2771 1 AA genotype also had increased organ dysfunction as demonstrated by fewer DAF of organ dysfunction compaied w ith control
- a response association of leucv, l/cystinyl aminopeptidase is2771 1 in a group of Caucasian ICU septic shock subjects who v ere tieated w ith vasopiessin For all variables besides 28-day suiv lval, data is given as 25 lh percentile [ median
- LNPEP leucyl/cystinyl aminopeptidase
- LNPEP leucyl/cystinyl aminopeptidase
- LNPEP rs 10051617 can be used to pi edict response to ⁇ asoptessin in subjects w ith septic shock using 28- day tov al and measures of organ dysfunction as outcome variables Of 103 vasopressin-treated and 103 matched-control subjects w ith septic shock, 72 and 81 were respectively genotyped toi LNPEP rs 10051637 Baseline character istics for subjects w ith genotypes are show n in Table 3 1 3 and Table 3 14 LNPEP rs 10051637 is in linkage disequilibrium w ith, foi example LNPEP isl 8059 and LNPEP G9419812A. which were also genotyped in this cohoit.
- Baseline characteristics of a matched-control group of Caucasian septic-shock subjects by leucy 1/cyst my 1 aminopeptidase is 10051637 genotype For age and APACHE II score. data is given as 25 lh percentile
- Tables 3.15, 3.16 and Tables 3.17 contain 28-day survival and organ dysfunction data for septic-shock subjects genotyped for LNPEP rsl0051637.
- Vasopressin-treated subjects w ith the LNPEP rs 10051637 GG genotype were also observed to have more organ dysfunction as demonstrated by fewer DAF of organ dysfunction In contiast. vasopressin-treated subjects w ith the LNPEP i s i 0051637 AG and AA genotypes had incieased survival (26 9c) compaied to controls (20 9c )
- LNPEP leucyl/cystinyl aminopeptidase
- LNPEP leucyl/cystinyl ciminopeptidase
- AVP rsl 410713 can be used to predict response to vasopressin in subjects with septic shock using 28-day survival and measures of organ dysfunction as outcome variables. Of 103 vasopressin-treated and 103 matched-control subjects with septic shock, 72 and 81 were respectively genotyped for AVP rs 1410713. Baseline
- N number of subjects.
- vasopressin AVP rs 1410713 genotype.
- AVP vasopressin
- Tables 3.20. 3.21 and 3.22 contain 28-day survival and organ dysfunction data for septic- shock subjects genoty ped for AVP rsl410713 Vasopressin -treated subjects w ith the AVP 1S14107 H AA genotype had a dramatically incieased survival (38 c /c ) compared to controls (0 7c) as demonstrated by the positive values in the AVP rs 1410713 AA DELTA column in Table 3 22 Furtheimore, v asopressin-treated subjects w ith the AVP rs 14107 H AA genotype weie observed to have less organ dysfunction as demonstrated by more DAF of organ dyst unction Vasopressin- treated subjects w ith AVP rs 1410713 AC genotype were also observed to have increased 28-day suiv ival (477r ) compared w ith that of control subjects (37%)
- Difteiencc in response association of arginine vasopiessin (AVP) isl410713 between cases (vasopressm-treated group) (Treat) and controls (vasopressin untreated matched contiol) (Cont) of Caucasian ICU subjects diagnosed with septic shock
- AVP arginine vasopiessin
- AVP rs857240 can be used to piedict response to vasopressin in subjects w ith septic shock using 28-day survival and measures of organ dysfunction as respective primary and secondary outcome variables Of 10 " ' vasopiessm-tieated and 103 matched-control subjects w ith septic shock, 73 and 83 were lespectively genotyped for LNPEP i s857240 Baseline characteristics for subjects w ith genotypes
- Tables 1 25, 1 26 and 1 27 contain 28-day survival and oigan dysfunction data for septic shock subjects genotyped for AVP is857240 Vasopiessin -treated subjects w ith the AVP rs857240 CT genotype had dramatically decreased survival if vasopressin-treated (29 c /c) compaied to contiols (41 c/ c) as demonstrated by the negative values in the AVP is857240 CT DELTA column in Table 1 27 Furthei moie.
- vasopiessin-treated subjects w ith the AVP rs857240 CT genotype were observed to have moie organ dysfunction than AVP rs857240 CT control subjects as demonstrated by more DAF of organ dysfunction
- vasopressin-treated subjects w ith the AVP rs857240 CC genotype had increased surv ival (41 c /c ) compared to controls ( 10 c /c ) as
- AVP arginine vasopiessin
- Baseline chaiacteristics of a gioup of vasopressin-tieated Caucasian ICU septic shock subjects by genotype ot aiginine vasopressin (AVP) is 857242 Foi age and APACHE II score, data is given as 2?"' peicentile
- Tables 3.30, 3.31 and 3.32 contain 28-day survival and organ dysfunction data for septic-shock subjects genotyped for AVP rs857242 Vasopressin -treated subjects w ith the AVP rs857242 AC genotype had a dramatically decieased surv ival (38 7c ) compared to controls (54 7c ) as
- vasopressin-treated subjects w ith the AVP rs857242 AC genotype were observed to have more organ dysfunction as demonstrated by more DAF of organ dysfunction.
- v asopressm-treated subjects w ith the AVP rs857242 CC genotype were observed to have increased surv ival (419r) compared w ith controls (307c ).
- rs857242 CC genotype were obseived to have increased 28-day surv ival (47%) compared w ith that of control subjects 017c ) as demonstrated by the positive values in the AVP rs857242 CC DELTA column in Table 3 32 Furthermore, vasopressin-treated subjects w ith the AVP rs857242 CC genotype were observed to have less organ dysfunction as demonstrated by more DAF of organ dysfunction
- AVP arginine v asopressin
- a response association of arginine vasopiessin (AVP) rs857242 in Caucasian septic-shock control subjects For all variables besides 28-day survival, data is given as 25 th percentile
- 75 th percentile For 28-day survival, data is given as % (N surv ived / N total) N, number of subjects
- AVPRlA Arginine Vasopressin Receptor Ia
- AVPRl A isl495027 can be used to piedict response to vasopiessin in subjects w ith septic shock using 28- K) day surviv al and measures of oigan dysfunction as lespective p ⁇ maiy and secondary outcome variables Of 103 vasopressin-tieated and 03 matched-control subjects w ith septic shock. 72 and 79 were respectively genotyped for AVPR l A rs 1495027 Baseline characteristics for subjects w ith genotypes are shown in Table 3 33 and Table 3 34
- Tables 1 15 1 16 and 1 17 contain 28-day survival and organ dysfunction data for septic-shock subjects genotyped for AVPRl A rs 1495027 Vasopiessin-treated subjects w ith the AVPRlA i s 1495027 TT had a dramatically decreased sui v ival (21 9c ) compaied to controls (46 9c ) as demonstrated by the negative values in the ⁇ .VPR1 A rs l495027 TT DELTA column in Table 1 17 Fuitheimoie.
- vasopressin-treated subjects w ith the AVPRl A tsl495Q27 TT genotype vveie obsei ved to have moie oigan dysfunction as demonstrated by fewei DAF of organ dysfunction
- vasopiessin-tieated subjects w ith the AVPR l A rsl495027 CC genotype weie shown to have incieased suiv ival (507r) over AVPR l A rs 1495027 CC contiols (247r) as demonstiated by the positive values in the AVPRl A rs 1495027 TT DELTA column in Table 1 17
- vasopressin subjects w ith the AVPR l A i sl495027 CC genotype had less oigan dysfunction as ev idenced by more DAF of organ dysfunction
- AVP rs857240, AVP rs857242, and AVPR l A rs 1495027 in subjects w ith septic shock can predict response to administration of vasopressin as measured by 28-day survival and/or DAF of organ dysfunction
- Subjects w ith genotypes including LNPEP rs 18059 CC.
- LNPEP rs2771 1 AA, LNPEP i s l 0051637 GG, AVP rs 1410713 CC, AVP rs857240 CT, AVP rs857242 AC and AVPR l A rs 1495027 TT should not be administered a vasopressin receptor agonist as this could
- LNPEP Leucyl/Cystinyl Aminopeptidase 2.1.1 LNPEP rsl8059 2.1.1.1 Systematic Inflammatory Response Syndrome - Caucasians
- Baseline ehaiacte ⁇ stics ol a cohort of Caucasian Subjects w ith septic shock by allele of leuc> l/c> stinyl aminopeptidase (LNPEP) is 18059 (CC vs CT/TT) For age and APACHE II scoie, data is given as 25 lh percentile / median / 75 th peicentile For all other vanables, data is
- K Baseline characteristics of a cohort of Caucasian Subjects with systematic inflammatory response syndrome by genotype of leucyl/cystinyl aminopeptidase (LNPEP) rs38041 (AA vs. GG/AG). For age and APACHE II score, data is given as 25 th percentile / median / 75* percentile. For all olher variables, data is given as c k (N survived / N total). N, number of subjects.
- LNPEP leucyl/cystinyl aminopeptidase
- Arginine Vasopressin (AVP) 2.2.1 AVP rs 1410713
- Baseline characteristics of a cohort of Caucasian Subjects w ith systematic inflammatory response syndrome by genotype of Arginine Vasopressin (AVP) rs 1410713 (AA vs. CC/AC).
- AVP Arginine Vasopressin
- FIG. 2 and TABLE 4.14 summarize important SNP-phenotype associations for AVP rs 1410713.
- Baseline characteristics of a cohort of Caucasian Subjects with sepsis by genotype of Arginine Vasopressin (AVP) rs 1410713 (AA vs. CC/AC).
- AVP Arginine Vasopressin
- C A N survived / N total).
- N number of sub ects.
- FIG. 3 and TABLE 4.16 summarize important SNP-phenotype associations for AVP rs 1410713.
- Baseline characteristics of a cohort of Caucasian Subjects w ith septic shock by genotype of Arginine Vasopressin (AVP) rs 1410713 (AA vs. CC/AC).
- AVP Arginine Vasopressin
- FIG. 4 and TABLE 4.18 summarize important SNP-phenotype associations for AVP rs 1410713.
- a Sepsis - Caucasians TABLE 4.19 gives the baseline characteristics (age, gender, APACHE Il score, medical vs. surgical diagnosis, shock upon admission and septic shock anytime) of 573 Caucasian Subjects with sepsis who were successfully genotyped at AVP rs857240. No significant differences were detected between the genotype groups on admission to the ICU.
- Baseline characteristics of a cohort of Caucasian Subjects with sepsis by genotype of Arginine Vasopressin (AVP) rs857240 (CC vs. CT/TT).
- AVP Arginine Vasopressin
- CC vs. CT/TT For age and APACHE II score, data is given as 25* percentile / median / 75 lh percentile.
- c k N survived / N total). N. number of subjects.
- Baseline characteristics of a cohort of Caucasian Subjects with septic shock by genotype of Arginine Vasopressin (AVP) rs857240 (CC vs. CT /TT).
- AVP Arginine Vasopressin
- CC vs. CT /TT For age and APACHE II score, data is given as 25 lh percentile / median / 75 m percentile. For all other variables, data is given as % (N survived / N total). N, number of sub ects.
- These findings indicate thai Caucasian subjects with septic shock who had either the TT or CT genotype at AVP rs857240 have less need of vasopressor and inotrope therapy, have less SIRS, and have a lower risk of organ dysfunction (renal and hepatic).
- FIG. 5 and TABLE 4.24 summarize important SNP-phenotype associations for AVP rs857242.
- FIG. 6 and TABLE 4.26 summarize important SNP-phenotype associations for AVP rs857242.
- Baseline characteristics of a cohort of Caucasian Subjects with septic shock by genotype of Arginine Vasopressin (AVP) rs857242 (AC/AA ⁇ s. CC).
- AVP Arginine Vasopressin
- FIG. 7 and TABLE 4.28 summarize important SNP-phenotype associations for AVP rs857242.
- AVPRlA Arginine Vasopressin Receptor Ia
- TABLE 4.29 gives the baseline characterisi ics (age, gender, APACHE II score, and medical vs. surgical diagnosis) of the 361 Caucasian septic shock subjects who were successfully genotyped at AVPRl A rs 1495027 (CC vs. CITTT). No s gnificant differences were detected between the two genotype groups on admission to the ICU.
- Baseline characteristics of a cohort of Caucasian Subjects with systematic inflammatory response syndrome by genotype of arginine vasopressin receptor I a (AVPRlA) r.s3803107 (CC/CT vs. TT).
- AVPRlA arginine vasopressin receptor I a
- CC/CT vs. TT arginine vasopressin receptor I a
- FIG. 8 and TABLE 4.32 summarize important SNP-phenotype association results for AVPRl A rs38O3107.
- AVPR l A arginine vasopressin receptor a
- RC/CT vs. TT CC/CT vs. TT
- FIG. 9 and TABLE 4.34 summarize important SNP-phenotype association results for AVPR I A rs3803107.
- H median / 75 th percentile. For 28-day survival, data is given as % (N survived / N total). N, number of sub ects.
- AVPR l A arginine vasopressin receptor Ia
- rs 10877970 CC vs. TT/CT
- TABLE 4.37 gives the baseline characteristics (age, gender, APACHE II score, medical vs. surgical diagnosis, sepsis upon admission, sepsis anytime, septic shock upon admission and septic shock anytime) of the 108 Asian systematic inflammatory response syndrome subjects who were successfully genotyped (C vs. T) at AVPR l A rs 10877970. No significant differences, other than a small difference in APACHE II score, were detected between the two allelic groups on admission to the ICLJ.
- FIG. 10 and TABLE 4.38 summarizes important SNP-phenotype association results for AVPR l A rs 10877970.
- R A language and environment
- LNPEP Leucyl/Cystinyl Aminopeptidase
- LNPEP leucyl/cystinyl aminopeptidase
- Table 5 2 show s the distribution of vasopressin administration by LNPEP rs 18059 genotype Subjects w ith the LNPEP isl 8059 CC genctype were obseived to have been administered
- Eiaseline characteristics for septic shock subjects with LNPEP rs2771 1 genotypes are shown in Table 5.3. No significant differences between the genotype groups were detected on admission to the ICU.
- Table 5.4 shows the distribution of vasopressin administration by LNPEP rs 10051637 genotype. Subjects w ith the GG genotype of LNPEP rs 10051637 were more frequently observed to be administered vasopressin (P ⁇ 0.001 ) compared to subjects who carried the AG or AA genotype of LNPEP rs 10051637 (TABLE 5.6).
- Table 5.4 shows the distribution of vasopressin administration by AVPR l A rs 1495027 genotype.
- Subjects with the AVPRl A rs 1495027 CT genotype had significantly increased use of vasopressin (P 0.0240) compared to subjects who carried either the CC or TT genotype of AVPR l A T AVPR 1 A rs 1495027 (TABLE 5.8).
- Examples 1 -3 show that polymorphisms of the AVP, AVPRl A and LNPEP genes are associated with altered outcome in critically ill subjects.
- the present example examines subjects w ith non-septic causes of systemic inflammatory response syndrome by analyzing SNP-phenotype interactions in subjects having undergone cardiopulmonary bypass surgery. If an AVP. AVPR 1 A, LNPEP or LRAP gene polymorphism was associated w ith altered survival and organ dysfunction, that polymorphism is also likely to be associated w ith changes in pro-inflammatory proteins such as serum granulocyte colony stimulating factor (GCSF), interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCPl ) 5 METHODS
- GCSF serum granulocyte colony stimulating factor
- IL-8 interleukin 8
- MCPl monocyte chemotactic protein 1
- LNPEP Leueyl/Cystinyl Aminopeptidase
- Baseline characteustics of a cohort of non-septic CSICU subjects diagnosed w ith systematic inflammatory response syndrome by genoty pe of leucyl/cystinyl aminopeptidase is l 8059 (CC vs CT vs TT)
- Baseline characteristics of a cohort of non-septic CSICU subjects diagnosed with systematic inflammatory response syndrome by genotype of leucyl/cystinyl aminopeptidase (LNPEP) rs2771 l (AA vs. GG/AG).
- LNPEP leucyl/cystinyl aminopeptidase
- LNPEP rs 100516.37 TABLE 6.5 summarizes the baseline characteristics of 70 non-septic SIRS subjects who were successfully genotyped (AA/ AG vs. GG) ai LNPEP rs 10051637. No significant differences between the genotype groups were detected on admission to the CSICU.
- Biomarkers are measured in /ml.
- TABLL 6.9 summa ⁇ zes the baseline chaia ⁇ e ⁇ stics of S7 non-septic SIRS subjects who weie genotvped at AVP rs857242 No significanl differences between the genotype groups weie detected on admission to the CSICU TABLE 6.9
- Baseline characteristics of a cohort of non-septic CSICU subjects diagnosed with systematic inflammatory response syndrome by genotype of Arginine Vaso ressin (AVP) rs857242.
- I O CC genotype have a decreased chemokine (GCSF) response after cardiopulmonary bypass surgery.
- GCSF chemokine
- Vaso ressin (AVP) rs857242 Biomarkers are measured in /ml.
- Biomarkers are measured in pg/ml.
- vasopressin AVP rs 1410713. rs857240. rs857242
- AVPRlA rs 1495027 the arginine vasopressin Al receptor
- LNPEP rs 18059, rs2771 I , and rs 10051637 gene are associated with response (measured as survival, organ dysfunction and need of life support) to AVP.
- markers m the ⁇ asopressinase gene (LNPEP rsl 8059, rs2771 1. and rsl0051637) ind the ⁇ asopiessin A l receptor gene (AVPRl A rsl495027) are also markers of increased use ot AVP in a cohort of critically ill subjects who have septic shock Accordingly, clinicians more fiequently administei infused AVP to subjects who have LNPEP genotypes rsl 8059 CC. rs2771 1 AA and 5 rs l 0051617 GG and subjects who have the AVPR l A genotype. isl495027 CT These genotypes also have a significantly decreased chance of surv ival when treated w ith infused AVP compared to comparable subjects who have septic shock but who are not infused w ith AVP (control)
- LNPEP rs 18059 CC, LNPEP rs2771 1 AA and LNPEP rs 10051617 GG are associated w ith decreased inflammatory ic-ponse (measured as GCSF and IL-8 response) to non- septic causes of systemic inflammatory iesponse syndrome (subjects having cardiopulmonaiy bypass surgeiy )
- vasopiessin receptor agonist(s) e g V-I ieceptor agonist, e g a V i a ieceptor agonist, e g an AVPRl agonist
- vasopiessin reeeptoi agon ⁇ st(s) dramatically decieases then sui uvdl and incieases the i isk ot oigan dysfunction
- vasopressin reeeptoi agonist rsl410711. rs857240 and is857242
- AV PRlA vasopressin A l receptor
- LNPEP LNPEP gene (rsl 8059, ⁇ s2771 1 and rsl 0051617) Subjects who have the AVP rs 1410711 AA or AC, rs857240 CC or rs857242 CC genotypes, the AVPR l A rsl 495027 CC genotv pe.
- vasopressin receptor agonist(s) e g V-I ieceptor agonist, e g a V i a ieceptor agonist, e g an AVPR l agonist
- v asopressin receptor agonist(s) dramatically increases their tract and decreases the risk of organ is dysf unction
- cardiac surgery requiring cardiopulmonary bypass cardiac surgery not requiring cardiopulmonary bypass, cardiac transplantation and hypotension
- dialysis-induced hypotension, autonomic neuropathy, trauma and hypotension are also likely to be administered a vasopressin receptor agonist and should also be genotypes for single nucleotide polymorphisms of the vasopressin (AVP) gene (rs 1410713.
- AVP vasopressin
- rs857240, and rs857242 the vasopressin A l receptor (AVPR l A) gene (rs 1495027), and the vasopressinase (LNPEP) gene (rs ! 8059, rs2771 1 and rsl 0051637).
- AVPR l A vasopressin A l receptor
- LNPEP vasopressinase
- vasopressin AVP
- AVPR l A vasopressin A l receptor
- LNPEP vasopressinase
- TABLE 7.2 shows that subjects who have he AVP rs 1410713 CC, AVP rs857240 CT. and AVP rs857242 AC genotypes w ho receive AVP infusion have decreased survival compared to subjects w ho have the AVP rs 1410713 CC, AVP rs857240 CT. and AVP rs857242 AC genotypes who do not receive AVP infusion.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008551611A JP2009523456A (en) | 2006-01-24 | 2007-01-24 | Vasopressin pathway polymorphism as an indicator of subject outcome in severe subjects |
MX2008009654A MX2008009654A (en) | 2006-01-24 | 2007-01-24 | Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects. |
CA002638773A CA2638773A1 (en) | 2006-01-24 | 2007-01-24 | Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects |
US12/162,066 US20090298711A1 (en) | 2006-01-24 | 2007-01-24 | Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects |
AU2007209725A AU2007209725A1 (en) | 2006-01-24 | 2007-01-24 | Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects |
EP07719352A EP1984546A4 (en) | 2006-01-24 | 2007-01-24 | Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76132806P | 2006-01-24 | 2006-01-24 | |
US60/761,328 | 2006-01-24 | ||
US79515706P | 2006-04-27 | 2006-04-27 | |
US60/795,157 | 2006-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007085087A1 true WO2007085087A1 (en) | 2007-08-02 |
Family
ID=38308805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2007/000111 WO2007085087A1 (en) | 2006-01-24 | 2007-01-24 | Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1984546A4 (en) |
JP (1) | JP2009523456A (en) |
AU (1) | AU2007209725A1 (en) |
CA (1) | CA2638773A1 (en) |
MX (1) | MX2008009654A (en) |
WO (1) | WO2007085087A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009033820A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009033783A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009033782A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009039981A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009043458A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
EP2789689A1 (en) | 2009-06-29 | 2014-10-15 | Luminex Corporation | Chimeric primers with hairpin conformations and methods of using same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989011548A1 (en) * | 1988-05-20 | 1989-11-30 | Cetus Corporation | Immobilized sequence-specific probes |
CA2498509A1 (en) * | 2002-05-17 | 2003-11-27 | Riken | Method of detecting gene polymorphism |
US20050244834A1 (en) * | 1999-09-10 | 2005-11-03 | Whitehead Institute For Biomedical Research | Single nucleotide polymorphisms in genes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033582A1 (en) * | 2002-06-03 | 2004-02-19 | Manling-Ma Edmonds | Human single nucleotide polymorphisms |
CA2519362A1 (en) * | 2003-03-19 | 2004-09-30 | The University Of British Columbia | Plasminogen activator inhibitor-1 (pai-1) haplotypes useful as indicators of patient outcome |
CA2542823C (en) * | 2003-10-21 | 2015-05-26 | Suntory Limited | Method for prognostic evaluation of carcinoma using anti-p-lap antibody |
JP2007527718A (en) * | 2004-03-04 | 2007-10-04 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Toll-like receptor 2 (TLR-2) haplotype predicts patient outcomes (OutcomeofPatients) |
JP2007525980A (en) * | 2004-03-04 | 2007-09-13 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Thrombomodulin (THBD) haplotype to predict patient outcome |
CA2479968A1 (en) * | 2004-09-01 | 2006-03-01 | Keith R. Walley | Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome |
-
2007
- 2007-01-24 EP EP07719352A patent/EP1984546A4/en not_active Withdrawn
- 2007-01-24 CA CA002638773A patent/CA2638773A1/en not_active Abandoned
- 2007-01-24 JP JP2008551611A patent/JP2009523456A/en active Pending
- 2007-01-24 MX MX2008009654A patent/MX2008009654A/en not_active Application Discontinuation
- 2007-01-24 WO PCT/CA2007/000111 patent/WO2007085087A1/en active Application Filing
- 2007-01-24 AU AU2007209725A patent/AU2007209725A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989011548A1 (en) * | 1988-05-20 | 1989-11-30 | Cetus Corporation | Immobilized sequence-specific probes |
US20050244834A1 (en) * | 1999-09-10 | 2005-11-03 | Whitehead Institute For Biomedical Research | Single nucleotide polymorphisms in genes |
CA2498509A1 (en) * | 2002-05-17 | 2003-11-27 | Riken | Method of detecting gene polymorphism |
Non-Patent Citations (3)
Title |
---|
DELMAS A. ET AL.: "Clinical review: Vasopressin and terlipressin in septic shock patients", CRITICAL CARE, vol. 9, no. 2, April 2005 (2005-04-01), pages 212 - 222, XP003016404 * |
SAITO S. ET AL.: "Catalog of 178 variations in the Japanse population among eight human genes encoding G protein-coupled receptors (GPCRs)", J. HUMAN GENETICS, vol. 48, no. 9, September 2003 (2003-09-01), pages 461 - 468, XP003016403 * |
See also references of EP1984546A4 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009033820A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009033783A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009033782A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009039981A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009043458A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009043457A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009033783A3 (en) * | 2007-09-11 | 2009-11-26 | Mondobiotech Laboratories Ag | Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis |
WO2009043457A3 (en) * | 2007-09-11 | 2009-11-26 | Mondobiotech Laboratories Ag | Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis |
WO2009039980A3 (en) * | 2007-09-11 | 2009-11-26 | Mondobiotech Laboratories Ag | Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection |
WO2009039981A3 (en) * | 2007-09-11 | 2009-11-26 | Mondobiotech Laboratories Ag | Use of (arg 8) vasopressin to treat eg s. pneumoniae infection |
WO2009043458A3 (en) * | 2007-09-11 | 2009-11-26 | Mondobiotech Laboratories Ag | Use of oxytocin to treat many diseases |
WO2009033820A3 (en) * | 2007-09-11 | 2009-11-26 | Mondobiotech Laboratories Ag | Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis |
WO2009033782A3 (en) * | 2007-09-11 | 2009-11-26 | Mondobiotech Laboratories Ag | Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis |
EP2789689A1 (en) | 2009-06-29 | 2014-10-15 | Luminex Corporation | Chimeric primers with hairpin conformations and methods of using same |
Also Published As
Publication number | Publication date |
---|---|
AU2007209725A1 (en) | 2007-08-02 |
JP2009523456A (en) | 2009-06-25 |
MX2008009654A (en) | 2009-01-15 |
EP1984546A1 (en) | 2008-10-29 |
EP1984546A4 (en) | 2009-09-23 |
CA2638773A1 (en) | 2007-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070281300A1 (en) | Thrombomodulin (Thbd) Haplotypes Predict Outcome | |
US20090176206A1 (en) | Toll-like receptor 2 (tlr-2) haplotypes predict outcome of patients | |
US20100041600A1 (en) | Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects | |
US20090298711A1 (en) | Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects | |
US20080026371A1 (en) | Protein C And Endothelial Protein C Receptor Polymorphisms As Indicators Of Subject Outcome | |
EP1984546A1 (en) | Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects | |
US20110110930A1 (en) | Mitogen-Activated Protein Kinase Kinase Kinase 14 (MAP3K14) Polymorphisms As Indicators of Subject Outcome in Critically Ill Subjects | |
US20100209413A1 (en) | Serpine1 polymorphisms are predictive of response to activated protein c administration and risk of death | |
US20110027184A1 (en) | Protein c pathway associated polymorphisms as response predictors to activated protein c or protein c-like compound administration | |
US20090148458A1 (en) | Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy | |
US20110171200A1 (en) | Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2638773 Country of ref document: CA Ref document number: 2008551611 Country of ref document: JP Ref document number: MX/A/2008/009654 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007209725 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007719352 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007209725 Country of ref document: AU Date of ref document: 20070124 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12162066 Country of ref document: US |